Medical Devices; Exemption From Premarket Notification; Class II Devices; Wheelchair Elevator, 14013-14015 [2013-04899]
Download as PDF
wreier-aviles on DSK5TPTVN1PROD with RULES
Federal Register / Vol. 78, No. 42 / Monday, March 4, 2013 / Rules and Regulations
jejunum, ileocecal junction, and colon
of cattle with BSE. The new scientific
data confirms the presence of limited
amounts of BSE infectivity in the small
intestine outside of the distal ileum of
classical BSE infected cattle under
experimental inoculation and field
conditions. The infectivity levels
reported in these studies were much
lower than the infectivity levels that
were previously demonstrated in the
distal ileum.
We have added several peer-reviewed
studies (Refs. 2 to 6) to the
administrative record. We invite
comment on those studies.
Additionally, the European Food
Safety authority (EFSA) Panel on
Biological Hazards (BIOHAZ) has
reviewed and evaluated new data as it
relates to the BSE epidemiological
situation in the European Union. We
have added the EFSA documents to the
administrative record as well (Refs. 7
and 8). We have evaluated the data from
the studies. Only trace amounts of
infectivity have been found in the
proximal ileum, jejunum, ileocecal
junction, and colon of cattle with
naturally occurring cases of BSE. We
tentatively conclude that the effect of
these traces of infectivity on the risk of
human or ruminant exposure to BSE in
the United States is negligible. The very
low levels of infectivity in parts of the
intestine other than the distal ileum, the
sharp decline in the prevalence of BSE
worldwide, FDA’s BSE-related
restrictions on the contents of animal
food and feed (see 21 CFR 589.2000 and
589.2001), and the extremely low
prevalence of BSE within cattle in the
United States due to the presence of
effective mitigations and compliance
with international standards suggest
that the risk from parts of the intestine
other than the distal ileum is extremely
low. We also note that the World
Organization for Animal Health
(formerly known as the Office
International des Epizooties or ‘‘OIE’’)
has not changed its definition of SRMs
to include any part of the small intestine
in addition to the distal ileum. Based on
this assessment, we tentatively conclude
that requiring the removal of additional
parts of the small intestine would not
provide a measurable risk reduction
compared to that already being achieved
by removal of the distal ileum in all
cattle and that it would be appropriate
to finalize our interim final rule without
changing any provisions related to the
small intestine. We invite comment on
this tentative conclusion.
II. Comments
Interested persons may submit either
electronic comments regarding this
VerDate Mar<15>2010
15:31 Mar 01, 2013
Jkt 229001
14013
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
III. References
HHS.
The following references have been
placed on display in the Division of
Dockets Management (see ADDRESSES)
and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday, and are available
electronically at https://
www.regulations.gov.
1. Terry, L.A., S. March, S.J. Ryder, et al.,
‘‘Detection of Disease Specific PrP in the
Distal Ileum of Cattle Exposed Orally to
the Agent of Bovine Spongiform
Encephalopathy,’’ Veterinary Record,
vol. 152, pp. 387–392, 2003.
2. Balkema-Buschmann, A., C. Fast, M. Kaatz,
et al., ‘‘Pathogenesis of Classical and
Atypical BSE in Cattle.’’ Preventive
Veterinary Medicine, vol. 102, pp. 112–
117, 2011.
3. Hoffmann, C., M. Eiden, M. Kaatz, et al.,
‘‘BSE Infectivity in Jejunum, Ileum and
Ileocaecal Junction of Incubating Cattle,’’
Veterinary Research, vol. 42, p. 21, 2011.
4. Kimura K. and M. Haritani, ‘‘Distribution
of Accumulated Prion Protein in a Cow
With Bovine Spongiform
Encephalopathy,’’ The Veterinary
Record, vol. 162, pp. 822–825, 2008.
5. Okada H., Y. Iwamaru, M. Imamura, et al.
‘‘Detection of Disease-Associated Prion
Protein in the Posterior Portion of the
Small Intestine Involving the Continuous
Peyer’s Patch in Cattle Orally Infected
With Bovine Spongiform
Encephalopathy Agent,’’ Transboundary
and Emerging Diseases, vol. 58(4), pp.
333–343, Aug. 2011.
6. Stack M., S.J. Moore, A. Vidal-Diez, et al.
‘‘Experimental Bovine Spongiform
Encephalopathy: Detection of PrP(SC) in
the Small Intestine Relative to Exposure
Dose and Age,’’ Journal of Comparative
Pathology, vol. 145, pp. 289–301, 2011.
7. ‘‘European Food Safety Authority (EFSA)
Panel on Biological Hazards (BIOHAZ),’’
EFSA Journal, vol. 1317, pp. 1–9, 2009.
8. ‘‘European Food Safety Authority (EFSA)
Panel on Biological Hazards (BIOHAZ),’’
EFSA Journal, vol. 9(3), p. 2104, 2011.
Dated: February 26, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–04869 Filed 3–1–13; 8:45 am]
BILLING CODE 4160–01–P
PO 00000
Frm 00015
Fmt 4700
Sfmt 4700
Food and Drug Administration
21 CFR Part 890
[Docket No. FDA–2011–P–0882]
Medical Devices; Exemption From
Premarket Notification; Class II
Devices; Wheelchair Elevator
AGENCY:
ACTION:
Food and Drug Administration,
Final order.
The Food and Drug
Administration (FDA) is publishing an
order granting a petition requesting
exemption from premarket notification
requirements for wheelchair elevator
devices commonly known as inclined
platform lifts and vertical platform lifts.
These devices are used to provide a
means for a person with a mobility
impairment caused by injury or other
disease to move from one level to
another, usually in a wheelchair. This
order exempts wheelchair elevators,
class II devices, from premarket
notification and establishes conditions
for exemption for this device that will
provide a reasonable assurance of the
safety and effectiveness of the device
without submission of a premarket
notification (510(k)). This exemption
from 510(k), subject to these conditions,
is immediately in effect for wheelchair
elevators. All other devices classified
under FDA’s wheelchair elevator
regulations, including attendantoperated stair climbing devices for
wheelchairs and portable platform lifts,
continue to require submission of
510(k)s. FDA is publishing this order in
accordance with the section of the Food,
Drug, and Cosmetic Act (the FD&C Act)
permitting the exemption of a device
from the requirement to submit a 510(k).
DATES: This order is effective March 4,
2013.
FOR FURTHER INFORMATION CONTACT:
Brian Pullin, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1554, Silver Spring,
MD 20993, 301–796–6455.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Statutory Background
Section 510(k) of the FD&C Act (21
U.S.C. 360(k)) and its implementing
regulations (21 CFR part 807) require
persons who propose to begin the
introduction or delivery for introduction
into interstate commerce for commercial
distribution of a device intended for
human use to submit a 510(k) to FDA.
E:\FR\FM\04MRR1.SGM
04MRR1
14014
Federal Register / Vol. 78, No. 42 / Monday, March 4, 2013 / Rules and Regulations
wreier-aviles on DSK5TPTVN1PROD with RULES
The device may not be marketed until
FDA finds it ‘‘substantially equivalent’’
within the meaning of section 513(i) of
the FD&C Act (21 U.S.C. 360c(i)) to a
legally marketed device that does not
require premarket approval.
On November 21, 1997, the President
signed into law the Food and Drug
Administration Modernization Act of
1997 (FDAMA) (Pub. L. 105–115),
section 206 of which added section
510(m) to the FD&C Act. Section
510(m)(1) of the FD&C Act requires
FDA, within 60 days after enactment of
FDAMA, to publish in the Federal
Register a list of each type of class II
device that does not require a report
under section 510(k) of the FD&C Act to
provide reasonable assurance of safety
and effectiveness. Section 510(m) of the
FD&C Act further provides that a 510(k)
will no longer be required for these
devices upon the date of publication of
the list in the Federal Register. FDA
published that list in the Federal
Register of January 21, 1998 (63 FR
3142).
Section 510(m)(2) of the FD&C Act
provides that FDA may exempt a device
from premarket notification
requirements on its own initiative, or
upon petition of an interested person, if
FDA determines that a 510(k) is not
necessary to provide reasonable
assurance of the safety and effectiveness
of the device. This section requires FDA
to publish in the Federal Register a
notice of intent to exempt a device, or
of the petition, and to provide a 30-day
comment period. FDA must publish in
the Federal Register its final
determination regarding the exemption
of the device that was the subject of the
notice. If FDA fails to respond to a
petition under this section within 180
days of receiving it, the petition shall be
deemed granted.
II. Criteria for Exemption
There are a number of factors FDA
may consider to determine whether a
510(k) is necessary to provide
reasonable assurance of the safety and
effectiveness of a class II device. These
factors are discussed in the guidance
that the Agency issued on February 19,
1998, entitled ‘‘Procedures for Class II
Device Exemptions From Premarket
Notification, Guidance for Industry and
CDRH Staff ’’ (Class II 510(k) Exemption
Guidance). That guidance can be
obtained through the Internet on the
Center for Devices and Radiological
Health home page at https://
www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/ucm080198.htm or
by sending an email request to
dsmica@fda.hhs.gov to receive an
VerDate Mar<15>2010
15:31 Mar 01, 2013
Jkt 229001
electronic copy of the document or send
a fax request to 301–847–8149 to receive
a hard copy. Please use the document
number 159 to identify the guidance
you are requesting.
III. Petition
On December 2, 2011, FDA received
a petition requesting an exemption from
premarket notification for a wheelchair
elevator commonly known as an
inclined platform lift and a vertical
platform lift. (See Docket No. FDA–
2011–P–0882.) These devices are
currently classified under 21 CFR
890.3930, Wheelchair elevator. On May
3, 2012, FDA responded to the petition
with a letter explaining that the
information provided in the petition
was insufficient for the Agency to assess
whether the risks posed by this type of
device could be sufficiently mitigated in
the absence of premarket notification
requirements. To address the Agency’s
concerns, the petitioner submitted
additional information regarding
standards that could be relied upon to
mitigate the device risks, which the
Agency received on June 7, 2012. This
restarted the 180-day clock under
section 510(m)(2) of the FD&C Act. (See
Class II Exemption Guidance, p. 3.)
In the Federal Register of June 1, 2012
(77 FR 32644), FDA published a notice
announcing that this petition had been
received and provided opportunity for
interested persons to submit comments
on the petition by July 2, 2012. FDA
received one comment supporting an
exemption from premarket notification
for this type of device. The comment
stated that these devices have been
produced for many years and have a
very good safety record. It noted that all
of these products already need to
comply with the FDA-recognized
American Society of Mechanical
Engineers (ASME) standard ‘‘ASME
A18.1 Safety Standard for Platform Lifts
and Stairway Chairlifts’’ (ASME A18.1),
which provides that these products are
to be built and certified to the
provisions of the National Electric Code
and the Canadian Standards Association
(CSA)/ASME standard ‘‘CSA B44.1/
ASME A17.5 Elevator and Escalator
Electrical Equipment’’ for elevator and
escalator electrical equipment.
FDA has assessed the need for 510(k)
clearance for this type of device against
the criteria laid out in the Class II 510(k)
Exemption Guidance and in 63 FR 3142,
and agrees they weigh in favor of 510(k)
exemption, as long as certain conditions
are met. FDA agrees that the risks posed
by the device and the characteristics of
the device necessary for its safe and
effective performance are well
established. FDA believes that changes
PO 00000
Frm 00016
Fmt 4700
Sfmt 4700
in the device that could affect safety and
effectiveness will be readily detectable
by certain types of routine analysis and
nonclinical testing, such as those
detailed in certain consensus standards.
Therefore, after reviewing the petition,
the additional information received on
June 7, 2012, and the comment on the
petition, FDA has determined that
premarket notification is not necessary
to assure the safety and effectiveness of
inclined and vertical platform lifts, as
long as the conditions for 510(k)
exemption listed in this document are
met. FDA responded to the petition by
letter dated December 3, 2012, to inform
the petitioner of this decision within the
180-day timeframe under section
510(m)(2) of the FD&C Act.
For clarity, this order: (1) Defines a
subset of wheelchair elevators classified
under § 890.3930 identified as
‘‘permanently mounted wheelchair
platform lifts’’ and (2) exempts this
subset of devices from premarket
notification requirements provided
certain conditions are met, which will
be codified in this classification
regulation. This order does not affect
other devices classified under
§ 890.3930, such as attendant-operated
stair climbing devices for wheelchairs
and portable platform lifts, which
remain subject to premarket notification
requirements, and does not change the
class of any of the devices classified
under this regulation, which all remain
in class II. These devices will remain
subject to current good manufacturing
practices requirements and other
general controls under the statute.
IV. Conditions for Exemption
This final order provides conditions
for exemption from premarket
notification on appropriate testing and
labeling of the device. The following
conditions must be met for the device to
be 510(k)-exempt: (1) Appropriate
analysis and nonclinical testing (such as
that outlined in the currently FDArecognized edition of ASME A18.1
‘‘Safety Standard for Platform Lifts and
Stairway Chair Lifts’’) must demonstrate
that the safety controls are adequate to
prevent a free fall of the platform in the
event of a device failure; (2) appropriate
analysis and nonclinical testing must
demonstrate the ability of the device to
withstand the rated load with an
appropriate factor of safety; (3)
appropriate analysis and nonclinical
testing must demonstrate the ability of
the enclosures to prevent the user from
falling from the device; and (4)
appropriate analysis and nonclinical
testing (such as that outlined in the
currently FDA-recognized edition of
AAMI/ANSI/IEC 60601–1–2, ‘‘Medical
E:\FR\FM\04MRR1.SGM
04MRR1
Federal Register / Vol. 78, No. 42 / Monday, March 4, 2013 / Rules and Regulations
Electrical Equipment—Part 1–2: General
Requirements for Safety—Collateral
Standard: Electromagnetic
Compatibility—Requirements and
Tests,’’ and ASME A18.1 ‘‘Safety
Standard for Platform Lifts and Stairway
Chair Lifts’’) must validate
electromagnetic compatibility and
electrical safety.
Firms are now exempt from 510(k)
requirements for vertical and inclined
platform lifts as long as they meet these
conditions of exemption. Firms must
comply with the particular mitigation
measures set forth in the conditions for
exemption or submit and receive
clearance for a 510(k) prior to
marketing.
V. Environmental Impact
The Agency has determined under 21
CFR 25.30(h) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
VI. Paperwork Reduction Act of 1995
This final order contains no collection
of information. Therefore, clearance by
the Office of Management and Budget
under the Paperwork Reduction Act of
1995 is not required.
List of Subjects in 21 CFR Part 890
Medical devices, Physical medicine
devices.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, 21 CFR part 890 is
amended as follows:
PART 890—PHYSICAL MEDICINE
DEVICES
1. The authority citation for 21 CFR
part 890 continues to read as follows:
■
Authority: 21 U.S.C. 351, 360, 360c, 360e,
360j, 371.
2. Section 890.3930 is revised to read
as follows:
■
wreier-aviles on DSK5TPTVN1PROD with RULES
§ 890.3930
Wheelchair elevator.
(a) Permanently mounted wheelchair
platform lift—(1) Identification. A
permanently mounted wheelchair
platform lift is a motorized vertical or
inclined platform lift device
permanently installed in one location
that is intended for use in mitigating
mobility impairment caused by injury or
other disease by providing a guided
platform to move a person from one
level to another, with or without a
wheelchair.
VerDate Mar<15>2010
15:31 Mar 01, 2013
Jkt 229001
(2) Classification. Class II. The
permanently mounted wheelchair
platform lift is exempt from premarket
notification procedures in subpart E of
part 807 of this chapter, subject to
§ 890.9 and the following conditions for
exemption:
(i) Appropriate analysis and
nonclinical testing (such as that
outlined in the currently FDArecognized edition of ASME A18.1
‘‘Safety Standard for Platform Lifts and
Stairway Chair Lifts’’) must demonstrate
that the safety controls are adequate to
prevent a free fall of the platform in the
event of a device failure;
(ii) Appropriate analysis and
nonclinical testing (such as that
outlined in the currently FDArecognized edition of ASME A18.1
‘‘Safety Standard for Platform Lifts and
Stairway Chair Lifts’’) must demonstrate
the ability of the device to withstand the
rated load with an appropriate factor of
safety;
(iii) Appropriate analysis and
nonclinical testing (such as that
outlined in the currently FDArecognized edition of ASME A18.1
‘‘Safety Standard for Platform Lifts and
Stairway Chair Lifts’’) must demonstrate
the ability of the enclosures to prevent
the user from falling from the device;
and
(iv) Appropriate analysis and
nonclinical testing (such as that
outlined in the currently FDArecognized editions of AAMI/ANSI/IEC
60601–1–2, ‘‘Medical Electrical
Equipment—Part 1–2: General
Requirements for Safety—Collateral
Standard: Electromagnetic
Compatibility—Requirements and
Tests,’’ and ASME A18.1 ‘‘Safety
Standard for Platform Lifts and Stairway
Chair Lifts’’) must validate
electromagnetic compatibility and
electrical safety.
(b) Portable wheelchair elevators—(1)
Identification. A portable wheelchair
elevator is a motorized lift device that
is not permanently mounted in one
location and that is intended for use in
mitigating mobility impairment caused
by injury or other disease by providing
a means to move a person, with or
without a wheelchair, from one level to
another (e.g., portable platform lifts,
attendant-operated stair climbing
devices for wheelchairs).
(2) Classification. Class II.
Dated: February 27, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–04899 Filed 3–1–13; 8:45 am]
BILLING CODE 4160–01–P
PO 00000
Frm 00017
Fmt 4700
Sfmt 4700
14015
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 890
[Docket No. FDA–2011–P–0804]
Medical Devices; Exemption From
Premarket Notification; Class II
Devices; Powered Patient Transport
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final order.
The Food and Drug
Administration (FDA) is publishing an
order granting a petition requesting
exemption from premarket notification
requirements for powered patient
transport devices commonly known as
stairway chair lifts. These devices are
used to assist in the transfer of a person
with a mobility impairment caused by
injury or other disease up and down
flights of stairs. This order exempts
stairway chair lifts, class II devices,
from premarket notification and
establishes conditions for exemption for
this device that will provide a
reasonable assurance of the safety and
effectiveness of the device without
submission of a premarket notification
(510(k)). This exemption from 510(k),
subject to these conditions, is
immediately in effect for stairway chair
lifts. All other devices classified under
FDA’s powered patient transport
regulations, including attendantoperated portable stair-climbing chairs
(which are different from wheelchairs)
continue to require submission of
510(k)s. FDA is publishing this order in
accordance with the section of the Food,
Drug, and Cosmetic Act (the FD&C Act)
permitting the exemption of a device
from the requirement to submit a 510(k).
DATES: This order is effective March 4,
2013.
FOR FURTHER INFORMATION CONTACT:
Brian Pullin, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 1554, Silver Spring,
MD 20993, 301–796–6455.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Statutory Background
Section 510(k) of the FD&C Act (21
U.S.C. 360(k)) and its implementing
regulations (21 CFR part 807) require
persons who propose to begin the
introduction or delivery for introduction
into interstate commerce for commercial
distribution of a device intended for
human use to submit a 510(k) to FDA.
The device may not be marketed until
E:\FR\FM\04MRR1.SGM
04MRR1
Agencies
[Federal Register Volume 78, Number 42 (Monday, March 4, 2013)]
[Rules and Regulations]
[Pages 14013-14015]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-04899]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 890
[Docket No. FDA-2011-P-0882]
Medical Devices; Exemption From Premarket Notification; Class II
Devices; Wheelchair Elevator
AGENCY: Food and Drug Administration, HHS.
ACTION: Final order.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is publishing an order
granting a petition requesting exemption from premarket notification
requirements for wheelchair elevator devices commonly known as inclined
platform lifts and vertical platform lifts. These devices are used to
provide a means for a person with a mobility impairment caused by
injury or other disease to move from one level to another, usually in a
wheelchair. This order exempts wheelchair elevators, class II devices,
from premarket notification and establishes conditions for exemption
for this device that will provide a reasonable assurance of the safety
and effectiveness of the device without submission of a premarket
notification (510(k)). This exemption from 510(k), subject to these
conditions, is immediately in effect for wheelchair elevators. All
other devices classified under FDA's wheelchair elevator regulations,
including attendant-operated stair climbing devices for wheelchairs and
portable platform lifts, continue to require submission of 510(k)s. FDA
is publishing this order in accordance with the section of the Food,
Drug, and Cosmetic Act (the FD&C Act) permitting the exemption of a
device from the requirement to submit a 510(k).
DATES: This order is effective March 4, 2013.
FOR FURTHER INFORMATION CONTACT: Brian Pullin, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1554, Silver Spring, MD 20993, 301-796-6455.
SUPPLEMENTARY INFORMATION:
I. Statutory Background
Section 510(k) of the FD&C Act (21 U.S.C. 360(k)) and its
implementing regulations (21 CFR part 807) require persons who propose
to begin the introduction or delivery for introduction into interstate
commerce for commercial distribution of a device intended for human use
to submit a 510(k) to FDA.
[[Page 14014]]
The device may not be marketed until FDA finds it ``substantially
equivalent'' within the meaning of section 513(i) of the FD&C Act (21
U.S.C. 360c(i)) to a legally marketed device that does not require
premarket approval.
On November 21, 1997, the President signed into law the Food and
Drug Administration Modernization Act of 1997 (FDAMA) (Pub. L. 105-
115), section 206 of which added section 510(m) to the FD&C Act.
Section 510(m)(1) of the FD&C Act requires FDA, within 60 days after
enactment of FDAMA, to publish in the Federal Register a list of each
type of class II device that does not require a report under section
510(k) of the FD&C Act to provide reasonable assurance of safety and
effectiveness. Section 510(m) of the FD&C Act further provides that a
510(k) will no longer be required for these devices upon the date of
publication of the list in the Federal Register. FDA published that
list in the Federal Register of January 21, 1998 (63 FR 3142).
Section 510(m)(2) of the FD&C Act provides that FDA may exempt a
device from premarket notification requirements on its own initiative,
or upon petition of an interested person, if FDA determines that a
510(k) is not necessary to provide reasonable assurance of the safety
and effectiveness of the device. This section requires FDA to publish
in the Federal Register a notice of intent to exempt a device, or of
the petition, and to provide a 30-day comment period. FDA must publish
in the Federal Register its final determination regarding the exemption
of the device that was the subject of the notice. If FDA fails to
respond to a petition under this section within 180 days of receiving
it, the petition shall be deemed granted.
II. Criteria for Exemption
There are a number of factors FDA may consider to determine whether
a 510(k) is necessary to provide reasonable assurance of the safety and
effectiveness of a class II device. These factors are discussed in the
guidance that the Agency issued on February 19, 1998, entitled
``Procedures for Class II Device Exemptions From Premarket
Notification, Guidance for Industry and CDRH Staff '' (Class II 510(k)
Exemption Guidance). That guidance can be obtained through the Internet
on the Center for Devices and Radiological Health home page at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080198.htm or by sending an email request to
dsmica@fda.hhs.gov to receive an electronic copy of the document or
send a fax request to 301-847-8149 to receive a hard copy. Please use
the document number 159 to identify the guidance you are requesting.
III. Petition
On December 2, 2011, FDA received a petition requesting an
exemption from premarket notification for a wheelchair elevator
commonly known as an inclined platform lift and a vertical platform
lift. (See Docket No. FDA-2011-P-0882.) These devices are currently
classified under 21 CFR 890.3930, Wheelchair elevator. On May 3, 2012,
FDA responded to the petition with a letter explaining that the
information provided in the petition was insufficient for the Agency to
assess whether the risks posed by this type of device could be
sufficiently mitigated in the absence of premarket notification
requirements. To address the Agency's concerns, the petitioner
submitted additional information regarding standards that could be
relied upon to mitigate the device risks, which the Agency received on
June 7, 2012. This restarted the 180-day clock under section 510(m)(2)
of the FD&C Act. (See Class II Exemption Guidance, p. 3.)
In the Federal Register of June 1, 2012 (77 FR 32644), FDA
published a notice announcing that this petition had been received and
provided opportunity for interested persons to submit comments on the
petition by July 2, 2012. FDA received one comment supporting an
exemption from premarket notification for this type of device. The
comment stated that these devices have been produced for many years and
have a very good safety record. It noted that all of these products
already need to comply with the FDA-recognized American Society of
Mechanical Engineers (ASME) standard ``ASME A18.1 Safety Standard for
Platform Lifts and Stairway Chairlifts'' (ASME A18.1), which provides
that these products are to be built and certified to the provisions of
the National Electric Code and the Canadian Standards Association
(CSA)/ASME standard ``CSA B44.1/ASME A17.5 Elevator and Escalator
Electrical Equipment'' for elevator and escalator electrical equipment.
FDA has assessed the need for 510(k) clearance for this type of
device against the criteria laid out in the Class II 510(k) Exemption
Guidance and in 63 FR 3142, and agrees they weigh in favor of 510(k)
exemption, as long as certain conditions are met. FDA agrees that the
risks posed by the device and the characteristics of the device
necessary for its safe and effective performance are well established.
FDA believes that changes in the device that could affect safety and
effectiveness will be readily detectable by certain types of routine
analysis and nonclinical testing, such as those detailed in certain
consensus standards. Therefore, after reviewing the petition, the
additional information received on June 7, 2012, and the comment on the
petition, FDA has determined that premarket notification is not
necessary to assure the safety and effectiveness of inclined and
vertical platform lifts, as long as the conditions for 510(k) exemption
listed in this document are met. FDA responded to the petition by
letter dated December 3, 2012, to inform the petitioner of this
decision within the 180-day timeframe under section 510(m)(2) of the
FD&C Act.
For clarity, this order: (1) Defines a subset of wheelchair
elevators classified under Sec. 890.3930 identified as ``permanently
mounted wheelchair platform lifts'' and (2) exempts this subset of
devices from premarket notification requirements provided certain
conditions are met, which will be codified in this classification
regulation. This order does not affect other devices classified under
Sec. 890.3930, such as attendant-operated stair climbing devices for
wheelchairs and portable platform lifts, which remain subject to
premarket notification requirements, and does not change the class of
any of the devices classified under this regulation, which all remain
in class II. These devices will remain subject to current good
manufacturing practices requirements and other general controls under
the statute.
IV. Conditions for Exemption
This final order provides conditions for exemption from premarket
notification on appropriate testing and labeling of the device. The
following conditions must be met for the device to be 510(k)-exempt:
(1) Appropriate analysis and nonclinical testing (such as that outlined
in the currently FDA-recognized edition of ASME A18.1 ``Safety Standard
for Platform Lifts and Stairway Chair Lifts'') must demonstrate that
the safety controls are adequate to prevent a free fall of the platform
in the event of a device failure; (2) appropriate analysis and
nonclinical testing must demonstrate the ability of the device to
withstand the rated load with an appropriate factor of safety; (3)
appropriate analysis and nonclinical testing must demonstrate the
ability of the enclosures to prevent the user from falling from the
device; and (4) appropriate analysis and nonclinical testing (such as
that outlined in the currently FDA-recognized edition of AAMI/ANSI/IEC
60601-1-2, ``Medical
[[Page 14015]]
Electrical Equipment--Part 1-2: General Requirements for Safety--
Collateral Standard: Electromagnetic Compatibility--Requirements and
Tests,'' and ASME A18.1 ``Safety Standard for Platform Lifts and
Stairway Chair Lifts'') must validate electromagnetic compatibility and
electrical safety.
Firms are now exempt from 510(k) requirements for vertical and
inclined platform lifts as long as they meet these conditions of
exemption. Firms must comply with the particular mitigation measures
set forth in the conditions for exemption or submit and receive
clearance for a 510(k) prior to marketing.
V. Environmental Impact
The Agency has determined under 21 CFR 25.30(h) that this action is
of a type that does not individually or cumulatively have a significant
effect on the human environment. Therefore, neither an environmental
assessment nor an environmental impact statement is required.
VI. Paperwork Reduction Act of 1995
This final order contains no collection of information. Therefore,
clearance by the Office of Management and Budget under the Paperwork
Reduction Act of 1995 is not required.
List of Subjects in 21 CFR Part 890
Medical devices, Physical medicine devices.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR part
890 is amended as follows:
PART 890--PHYSICAL MEDICINE DEVICES
0
1. The authority citation for 21 CFR part 890 continues to read as
follows:
Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 371.
0
2. Section 890.3930 is revised to read as follows:
Sec. 890.3930 Wheelchair elevator.
(a) Permanently mounted wheelchair platform lift--(1)
Identification. A permanently mounted wheelchair platform lift is a
motorized vertical or inclined platform lift device permanently
installed in one location that is intended for use in mitigating
mobility impairment caused by injury or other disease by providing a
guided platform to move a person from one level to another, with or
without a wheelchair.
(2) Classification. Class II. The permanently mounted wheelchair
platform lift is exempt from premarket notification procedures in
subpart E of part 807 of this chapter, subject to Sec. 890.9 and the
following conditions for exemption:
(i) Appropriate analysis and nonclinical testing (such as that
outlined in the currently FDA-recognized edition of ASME A18.1 ``Safety
Standard for Platform Lifts and Stairway Chair Lifts'') must
demonstrate that the safety controls are adequate to prevent a free
fall of the platform in the event of a device failure;
(ii) Appropriate analysis and nonclinical testing (such as that
outlined in the currently FDA-recognized edition of ASME A18.1 ``Safety
Standard for Platform Lifts and Stairway Chair Lifts'') must
demonstrate the ability of the device to withstand the rated load with
an appropriate factor of safety;
(iii) Appropriate analysis and nonclinical testing (such as that
outlined in the currently FDA-recognized edition of ASME A18.1 ``Safety
Standard for Platform Lifts and Stairway Chair Lifts'') must
demonstrate the ability of the enclosures to prevent the user from
falling from the device; and
(iv) Appropriate analysis and nonclinical testing (such as that
outlined in the currently FDA-recognized editions of AAMI/ANSI/IEC
60601-1-2, ``Medical Electrical Equipment--Part 1-2: General
Requirements for Safety--Collateral Standard: Electromagnetic
Compatibility--Requirements and Tests,'' and ASME A18.1 ``Safety
Standard for Platform Lifts and Stairway Chair Lifts'') must validate
electromagnetic compatibility and electrical safety.
(b) Portable wheelchair elevators--(1) Identification. A portable
wheelchair elevator is a motorized lift device that is not permanently
mounted in one location and that is intended for use in mitigating
mobility impairment caused by injury or other disease by providing a
means to move a person, with or without a wheelchair, from one level to
another (e.g., portable platform lifts, attendant-operated stair
climbing devices for wheelchairs).
(2) Classification. Class II.
Dated: February 27, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-04899 Filed 3-1-13; 8:45 am]
BILLING CODE 4160-01-P